Newsroom

August 4th, 2022: Myelo Therapeutics to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

July 28th, 2022: Myelo Therapeutics Receives Additional NIAID Funding For Development Myelo001 in Acute Radiation Syndrome

February 13th, 2022: Myelo Therapeutics Receives Scientific Advice by EMA for the development of Myelo001 for Acute Radiation Syndrome

June 4th, 2021: Myelo Therapeutics Receives Additional NIAID funding to Advance Development of Myelo001 in Acute Radiation Syndrome

March 3rd, 2021: Myelo Therapeutics Expands NIH-NIAID Collaboration and Joins Bayer Pharmaceuticals Incubator

June 26th, 2020: Myelo Therapeutics Closes Financing Round and Gains Strong Backing of Eckert & Ziegler Group.

May 11th, 2020: Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million for Development of Myelo001 as Treatment for Acute Radiation Syndrome.